AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Onconova Therapeutics, Inc.
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG02316KX83
7.18▼ 0.03 (-0.40%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
7.21
Day's Range
7.07 – 7.74
52-Week Range
7.07 – 43.14
Volume
245.0K
Avg Volume
13.5K
Share Statistics
Shares Outstanding
Employees
—
Exchange
XNAS
Listed
—
Share count as of August 12, 2026

Onconova Therapeutics, Inc. (ONTX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Onconova Therapeutics, Inc. (ONTX)
What is Onconova Therapeutics, Inc.'s Market Cap?
Onconova Therapeutics, Inc.'s Market Cap is $110.4M, based on as-reported figures from SEC (XBRL) filings.
What is Onconova Therapeutics, Inc.'s Enterprise Value?
Onconova Therapeutics, Inc.'s Enterprise Value is $105.3M, based on as-reported figures from SEC (XBRL) filings.
What is Onconova Therapeutics, Inc.'s Price / Sales?
Onconova Therapeutics, Inc.'s Price / Sales is 39.6×, based on as-reported figures from SEC (XBRL) filings.
What is Onconova Therapeutics, Inc.'s EV / Revenue?
Onconova Therapeutics, Inc.'s EV / Revenue is 37.8×, based on as-reported figures from SEC (XBRL) filings.
What is Onconova Therapeutics, Inc.'s EV / EBITDA?
Onconova Therapeutics, Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Onconova Therapeutics, Inc.'s Revenue (TTM)?
Onconova Therapeutics, Inc.'s Revenue (TTM) is $2.8M, based on as-reported figures from SEC (XBRL) filings.
What is Onconova Therapeutics, Inc.'s Net Income (TTM)?
Onconova Therapeutics, Inc.'s Net Income (TTM) is -$21.6M, based on as-reported figures from SEC (XBRL) filings.
What is Onconova Therapeutics, Inc.'s EBITDA?
Onconova Therapeutics, Inc.'s EBITDA is -$21.4M, based on as-reported figures from SEC (XBRL) filings.
What is Onconova Therapeutics, Inc.'s Diluted EPS (TTM)?
Onconova Therapeutics, Inc.'s Diluted EPS (TTM) is -1.40, based on as-reported figures from SEC (XBRL) filings.
What is Onconova Therapeutics, Inc.'s EBITDA Margin?
Onconova Therapeutics, Inc.'s EBITDA Margin is -766.9%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ONTXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Condensed Consolidated Statements of Operations
Revenue——
YoY growth——-100.0%-100.0%
Operating expenses:
Research and development
General and administrative
Other operating income———
Total operating expenses
% of revenue————
Loss from operations
% of revenue————
Change in fair value of warrant liability
Other (loss) income, net
Net (loss) income
% of revenue————
Net (loss) income attributable to common stockholders, basic
Net (loss) income attributable to common stockholders, diluted
Net (loss) income per share of common stock, basic (in dollars per share)
Net (loss) income per share of common stock, diluted (in dollars per share)
Net (loss) income attributable to Series C Preferred stockholders, basic
Net (loss) income attributable to Series C Preferred stockholders, diluted
Weighted-average shares of Series C Preferred outstanding, basic (in shares)
Weighted-average shares of Series C Preferred outstanding, diluted (in shares)—
Net (loss) income per share of Series C Preferred, basic (in dollars per share)
Net (loss) income per share of Series C Preferred, diluted (in dollars per share)—